Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.440 UNCHANGED
Delayed Quote Updated: 7:00 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors ↗
NARCAN's market lead persists despite pricing pressure, signaling the brand's resilience as the company executes its turnaround. 
Via The Motley Fool
Topics Earnings
News headline image
Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript ↗
Revenue fell 52% on delivery timing, but debt dropped 55% and guidance rose on margins. 
Via The Motley Fool
Topics Earnings
Emergent BioSolutions (NYSE:EBS) Shares Fall as Q3 2026 Revenue Misses and Adjusted EBITDA Turns Negative ↗
Via Chartmill
News headline image
Emergent Biosolutions Q3 Earnings Call Highlights ↗
Emergent Biosolutions (NYSE:EBS) reported third-quarter revenue within its guidance range and updated its full-year outlook, while continuing a multiyear transformation focused on cost control, debt... 
Via MarketBeat
Topics Earnings Economy
Emergent BioSolutions (NYSE:EBS) Beats Q2 Estimates, but Stock Drops on NARCAN Impairment and Restructuring Costs ↗
Via Chartmill
After-Hours Gainers and Losers: Nov. 2, 2026 Postmarket Review ↗
Via Chartmill
News headline image
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
From Emergent BioSolutions Inc.
Via Business Wire
News headline image
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
From Emergent BioSolutions Inc.
Via Business Wire
News headline image
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
From Emergent BioSolutions Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
From Emergent BioSolutions
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
From Emergent BioSolutions
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript ↗
MCM deliveries surge but naloxone competition forces restructuring and guidance cuts. 
Via The Motley Fool
Topics Earnings
News headline image
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Emergent Biosolutions Q2 Earnings Call Highlights ↗
Emergent Biosolutions (NYSE:EBS) reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S.... 
Via MarketBeat
Topics Earnings Economy
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.